Abstract:

ABSTRACT  Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprises Wegener granulomatosis, microscopic polyangiitis, Churg– Strauss syndrome and renal-limited vasculitis. Some new point of views had drawn along with the progress of evidence-based medicine: Glucocorticoids and cyclophosphamide are still commonly used to induce remission in generalized disease, and intravenous cyclophosphamide is better than oral cyclophosphamide with less side effects. Plasma exchange could used in life-threatening AASV; Methotrexate as a less-toxic alternative to cyclophosphamide to induce remission in early systemic AASV. Furthermore, rituximab is equally as effective as cyclophosphamide for induction of remission in AASV and might become the standard of therapy in the near future. Low-dose steroids plus azathioprine could be used as maintenance therapy; Molecules that block these pathways that are essential in the pathogenesis of AASV have shown benefit in animal models, providing hope for less-toxic therapies。This review highlights novel view of treatment of these diseases based several clinical trials.

Key words: Keywords , systemic vasculitis , antineutrophil cytoplasmic antibody , immunosuppressive agents